Autopsy report · NCT02784483

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

“Based on FDA requirements”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 2 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Yale University

Sponsor type

University, hospital or other

Conditions

Asymptomatic Myeloma

Interventions

Atezolizumab (1200mg via IV infusion)

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Perceval S Aortic Heart Valve Study- North America
  “FDA approval” (71% match in meaning)
• MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly
  “FDA hold on the project” (68% match in meaning)
• OTX-14-002: Device Exposure Registry
  “On going discussions with FDA” (67% match in meaning)
• Safety of SP-420 in the Treatment of Transfusional Iron Overload
  “Study is on hold by FDA in the US.” (63% match in meaning)
• Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
  “FDA reviewing” (62% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.